Related Experiment Video

Updated: Jun 10, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer

H Bolek1, S C Yazgan1, E Yekedüz2

  • 1Department of Medical Oncology, Ankara University School of Medicine, Ankara; Ankara University Cancer Research Institute, Ankara, Turkey.

ESMO Open
|October 19, 2024
PubMed

Insights

Androgen receptor pathway inhibitors (ARPIs) effectively treat prostate cancer. Understanding their drug interactions, especially in elderly patients, is crucial for safe and effective care.

Area of Science:

  • Oncology
  • Pharmacology
  • Internal Medicine

Background:

  • Prostate cancer is a significant global health issue requiring effective treatments.
  • Androgen receptor pathway inhibitors (ARPIs) are key therapies for metastatic and non-metastatic prostate cancer.
  • Elderly patients with prostate cancer often have comorbidities, increasing the risk of drug interactions.

Purpose of the Study:

  • To review the efficacy of ARPIs in prostate cancer management.
  • To elucidate drug-drug interactions associated with ARPIs.
  • To emphasize the importance of vigilant drug management in optimizing patient care.

Main Methods:

  • Review of current literature on ARPIs (abiraterone acetate, enzalutamide, apalutamide) and their clinical efficacy.
  • Analysis of known drug-drug interaction pathways, including CYP450 enzyme involvement (CYP2D6, CYP3A4).
  • Discussion of clinical implications for managing patients on ARPIs, particularly the elderly population.

Main Results:

  • ARPIs demonstrate significant efficacy in treating prostate cancer by inhibiting androgen synthesis or AR signaling.
  • Abiraterone acetate inhibits CYP2D6, while enzalutamide and apalutamide can induce CYP3A4, leading to potential interactions.
  • These interactions can affect the efficacy and safety of co-administered medications.

Conclusions:

  • ARPIs are vital for prostate cancer treatment, but their use requires careful consideration of potential drug interactions.
  • Thorough understanding of pharmacokinetic and pharmacodynamic interactions is essential for safe prescribing.
  • Proactive drug management strategies are necessary to optimize therapeutic outcomes and minimize adverse events in patients receiving ARPIs.
Keywords:
abiraterone acetateapalutamidedarolutamidedrug-drug interactionenzalutamideprostate cancer

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.5K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

Related Concept Videos

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
499
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
109
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
129